Stay updated on Obeldesivir Study in High-risk COVID-19: Clinical Trial
Sign up to get notified when there's something new on the Obeldesivir Study in High-risk COVID-19: Clinical Trial page.

Latest updates to the Obeldesivir Study in High-risk COVID-19: Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedThe web page has undergone significant changes, including the removal of detailed information about a clinical study for the drug obeldesivir (GS-5245) related to COVID-19, and the revision number has been updated from v2.14.4 to v2.15.0.SummaryDifference9%
- Check19 days agoChange DetectedThe web page has updated its version from v2.14.3 to v2.14.4, and the date has changed from March 25, 2025, to December 20, 2024.SummaryDifference0.7%
- Check27 days agoChange DetectedThe page has updated its versioning information, moving from Revision v2.14.2 to v2.14.3, and has changed the last update date from December 20, 2024, to March 25, 2025.SummaryDifference0.5%
- Check63 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
- Check77 days agoChange DetectedThe page now includes a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference1%
- Check85 days agoChange DetectedThe website has been updated from version v2.14.1 to v2.14.2.SummaryDifference0.1%
Stay in the know with updates to Obeldesivir Study in High-risk COVID-19: Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Obeldesivir Study in High-risk COVID-19: Clinical Trial page.